Article

Guidelines on good clinical laboratory practice: Bridging operations between research and clinical research laboratories

PPD Inc., 929 North Front Street, Wilmington, NC 28401-3331, United States.
Journal of Pharmaceutical and Biomedical Analysis (Impact Factor: 2.83). 02/2008; 46(1):18-29. DOI: 10.1016/j.jpba.2007.10.010
Source: PubMed

ABSTRACT A set of Good Clinical Laboratory Practice (GCLP) standards that embraces both the research and clinical aspects of GLP were developed utilizing a variety of collected regulatory and guidance material. We describe eleven core elements that constitute the GCLP standards with the objective of filling a gap for laboratory guidance, based on IND sponsor requirements, for conducting laboratory testing using specimens from human clinical trials. These GCLP standards provide guidance on implementing GLP requirements that are critical for laboratory operations, such as performance of protocol-mandated safety assays, peripheral blood mononuclear cell processing and immunological or endpoint assays from biological interventions on IND-registered clinical trials. The expectation is that compliance with the GCLP standards, monitored annually by external audits, will allow research and development laboratories to maintain data integrity and to provide immunogenicity, safety, and product efficacy data that is repeatable, reliable, auditable and that can be easily reconstructed in a research setting.

Download full-text

Full-text

Available from: Isaac Rodriguez-Chavez, Mar 11, 2014
2 Followers
 · 
248 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Regulated drug bioanalysis (i.e., determination of drug concentrations in biological matrices for regulated studies) usually refers to animal toxicokinetics, bioavailability/bioequivalence and clinical pharmacokinetic studies. However, there is another important regulated drug bioanalysis - therapeutic drug management (TDM). In the USA, TDM is regulated by Clinical Laboratory Improvement Amendments. In this article, we review and compare human pharmacokinetic sample analysis and TDM sample analysis. The US FDA/Bioanalytical Method Validation Guidance and the American Association for Clinical Chemistry/TDM Roundtable Recommended Generic Assay Validation Guidance are also compared. Some regulated drug bioanalysis issues, such as terminology, validation concepts and acceptance criteria, are discussed. Fostering interaction between bioanalysts from pharmaceutical science and clinical chemistry and reducing the regulatory gaps between different agencies for drug bioanalysis is our objective.
    Bioanalysis 08/2012; 4(15):1919-31. DOI:10.4155/bio.12.157 · 3.03 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is the most important cause of dementia in the elderly. The molecular alterations preceding this neurodegenerative pathology may take place even 20 years before its clinical appearance. In this context, the discovery of biomarkers in biological fluids enabling an early presymptomatic diagnosis as well as discrimination from other types of dementia is eagerly awaited. In particular, since the traditional markers obtained both from cerebrospinal fluid inspection and neuroimaging approaches have not achieved a broad clinical application, research efforts have been focused on the development and validation of biomarkers in blood. The benefit of searching for blood-based candidate biomarkers is evident due to the easiness and non-invasiveness nature of blood samples collection compared with any other body fluid. As a result, blood may constitute a rich source of disease biomarkers. Interestingly, among the technological platforms used to perform research into the biomarker discovery arena, proteomics has attained more recent consideration. In the present review, we provide a comprehensive assessment of patterns of biomarkers detected in plasma and serum specimens for the diagnosis of AD by employing proteomic approaches. Currently, growing evidence suggests that blood protein signatures are helpful to increase the likelihood of successful diagnosis of AD. Accordingly, this area of research promises to yield exciting results in the next future.
    Progress in Neurobiology 06/2012; 101. DOI:10.1016/j.pneurobio.2012.06.007 · 10.30 Impact Factor
  • Source